PURPOSE OF REVIEW: The focus of this review is on the current knowledge on epidemiology, pathology and treatment of HIV-associated Hodgkin lymphoma (HIV-HL). RECENT FINDINGS: Among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma was recently observed. However, the relationship between HIV infection, AIDS and Hodgkin lymphoma is still unclear. SUMMARY: In the highly active antiretroviral therapy era, HIV-infected people seem to be at increased risk of Hodgkin lymphoma than in first years of the epidemic. In these persons with improved immunity, increased CD4+ T cells provide antiapoptotic pathways and mechanisms for immune escape by tumor cells, as occurs in classic Hodgkin lymphoma among people without AIDS. Several studies have documented a significant difference in the distribution of Hodgkin lymphoma subtypes in HIV-infected persons as compared with Hodgkin lymphoma in HIV-uninfected population. HIV-HL exhibits special features related to the cellular background and the abundance of the neoplastic cell population, respectively. The fact that latent membrane protein 1 is expressed in virtually all HIV-HL cases suggests that Epstein-Barr virus plays an etiological role in the pathogenesis of HIV-HL. Recent advances in combined therapies, which are beginning to show promise in the treatment of this HIV-associated disorder, are discussed.
PURPOSE OF REVIEW: The focus of this review is on the current knowledge on epidemiology, pathology and treatment of HIV-associated Hodgkin lymphoma (HIV-HL). RECENT FINDINGS: Among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma was recently observed. However, the relationship between HIV infection, AIDS and Hodgkin lymphoma is still unclear. SUMMARY: In the highly active antiretroviral therapy era, HIV-infected people seem to be at increased risk of Hodgkin lymphoma than in first years of the epidemic. In these persons with improved immunity, increased CD4+ T cells provide antiapoptotic pathways and mechanisms for immune escape by tumor cells, as occurs in classic Hodgkin lymphoma among people without AIDS. Several studies have documented a significant difference in the distribution of Hodgkin lymphoma subtypes in HIV-infectedpersons as compared with Hodgkin lymphoma in HIV-uninfected population. HIV-HL exhibits special features related to the cellular background and the abundance of the neoplastic cell population, respectively. The fact that latent membrane protein 1 is expressed in virtually all HIV-HL cases suggests that Epstein-Barr virus plays an etiological role in the pathogenesis of HIV-HL. Recent advances in combined therapies, which are beginning to show promise in the treatment of this HIV-associated disorder, are discussed.
Authors: Yueh-Ying Han; Gregg E Dinse; David M Umbach; Devra L Davis; Joel L Weissfeld Journal: Cancer Causes Control Date: 2010-04-07 Impact factor: 2.506
Authors: Emilie Lanoy; Philip S Rosenberg; Fabien Fily; Anne-Sophie Lascaux; Valerie Martinez; Maria Partisani; Isabelle Poizot-Martin; Elisabeth Rouveix; Eric A Engels; Dominique Costagliola; James J Goedert Journal: Blood Date: 2011-05-06 Impact factor: 22.113
Authors: Manfred Hensel; Armin Goetzenich; Thomas Lutz; Albrecht Stoehr; Arend Moll; Jürgen Rockstroh; Nicola Hanhoff; Hans Jäger; Franz Mosthaf Journal: Dtsch Arztebl Int Date: 2011-02-25 Impact factor: 5.594
Authors: Lauro Ferreira da Silva Pinto Neto; Maria da Conceição Milanez; Jonathan Eric Golub; Angelica Espinosa Barbosa Miranda Journal: Rev Soc Bras Med Trop Date: 2012-12 Impact factor: 1.581